The flagship plant Sputnik Technopolis, part of the R-Pharm group of companies, is the largest biotechnological production in Russia and one of the largest in Eastern Europe.
The total volume of investments in the project of R-Pharm, RDIF and the Government of Moscow aimed at launching the production of the domestic vaccine against coronavirus infection Sputnik V for the implementation of national and city vaccination programs
amounted to more than 10 billion rubles.
Built in record time for the first wave of the pandemic, the pharmaceutical complex has an area of about 20 thousand square meters, of which 70% are clean rooms.